

Depression and anxiety in the developing world: is it time to medicalise the suffering

Item Type	Article
Authors	Stein, D.J.;Gureje, O.
Citation	Stein DJ, Gureje O. Depression and anxiety in the developing world: is it time to medicalise the suffering?
Journal	The Lancet
Rights	Attribution 3.0 United States
Download date	2025-06-01 19:58:23
Item License	http://creativecommons.org/licenses/by/3.0/us/
Link to Item	https://infospace.mrc.ac.za/handle/11288/595274

Depression and anxiety in the developing world: is it time to medicalise the suffering?

It stands to reason that when life's circumstances are harsh, people will feel stressed or depressed. Poverty, violence, and infectious disease, including HIV/AIDS, in the developing world, and in the lower socioeconomic strata of the developed world, lead to anguish and despair.¹ Such responses can readily be understood as normal responses to abnormal circumstances. There has perhaps been a tendency to regard this kind of mental suffering as a meaningful response, and therefore as a phenomenon that lies on the periphery of medicine proper. The prominence of communicable disease in poor regions and classes may further marginalise the medical status of psychological symptoms.

It is time for a change in perspective. Poverty and depression are closely linked,² and violence can lead to post-traumatic stress disorder and other psychiatric diseases. Nevertheless, depression and anxiety disorders, as well as resilience to these conditions, are phenomena that cut across rich and poor countries and classes. Depression and anxiety disorders are associated with suffering, but they are also underpinned by characteristic psychobiological dysfunctions. And they respond to specific medical interventions.

Support for a change in perspective is found in a range of data, some from recent studies. First, there are data on the prevalence of and disability associated with depression and anxiety disorders in the developing world. The WHO World Mental Health Survey Consortium,³ in the largest and most sophisticated cross-national survey of psychiatric disorders so far, recently confirmed previous work that, worldwide, mental illness is highly prevalent, associated with significant impairment, and often untreated. Undertreatment is particularly problematic in the developing world. The Global Burden of Disease study⁴ found that even though the share of disease burden from depression is lower in the developing than in the developed world, depression in 2000, as in 1990, caused the largest amount of non-fatal burden worldwide.

Second, there is increased understanding of the psychobiological underpinnings of depression and anxiety disorders. Some of this knowledge is consistent with a view that depression and anxiety is a normal defence that has adaptive value.⁵ But research also documents clear deficits in mood and anxiety disorders. Post-traumatic stress disorder, for example, is characterised by allostasis of the endocrine system, and by reduced volume of the hippocampus.⁶ Conversely, there is growing understanding of factors that play a role in resilience to such deficits, despite exposure to adversity.⁷

Third, there are data on the efficacy of specific medical interventions, not only in general but also in people living in the adverse circumstances of the developing world. Patel et al,⁸ for example, found that the antidepressant fluoxetine was superior over the short term to both placebo and counselling for depression in primary care in India. Bolton et al⁹ showed that

Rights were not granted to include this image in electronic media. Please refer to the printed journal.

Patient in makeshift mental home chained to table

Patients are chained to prevent them running away (Monrovia, Liberia, Aug 29, 2003).

interpersonal therapy for depression was better than treatment as usual in Uganda. Modest interventions can have a substantial effect on symptoms and impairment in the developing world.¹⁰ Cost-effectiveness analyses support the value of treatment,¹¹ although additional research is needed to maximise effectiveness in the developing world, where cultural and health systems might affect the applicability of findings from efficacy trials.

Are there risks to medicalising suffering? Philosophers and sociologists have warned against the overextension of the medical gaze.^{12,13} Certainly, if we focus only on pharmacotherapy and psychotherapy, we run the risk of failing to address key societal risk-factors for depression and anxiety (eg, poverty, gender inequity). There are no good data that conceptualising depression and anxiety as medical disorders detracts from such broader efforts. Nevertheless, creative interventions other than pharmacotherapy and individual psychotherapy should be studied. In the developing world, various kinds of community programmes might prove effective.

At the same time, a medical perspective has potential advantages. For one thing, such a perspective is consistent with an evidence-based approach to problem-solving—adopting evidence-based health policies and medical interventions seems rational. Such a stance potentially avoids some of the stigma of suffering. The Global Forum for Health Research¹⁴ argues that health indicators are more than mere indexes of suffering: they can serve as key targets for economists. Focusing on such indicators is a particularly efficient way for governments to invest.

Some basic changes will be needed if we are to take this medical turn. Much as doctors needed to be trained to diagnose depression in patients with cancer or stroke (despite the understandability of being depressed in such conditions), so practitioners in the developing world will require training to screen for depression and anxiety disorders (despite the ubiquity of such diseases).^{15,16} Diagnostic criteria might require updating. For example, criteria for generalised anxiety disorder state that the worry must be excessive, resulting in an underestimation of symptoms of generalised anxiety disorder in a stressed community.¹⁷ Parallel efforts to increase mental-health literacy in communities are crucial.¹⁸

Further, policy initiatives are required that encompass reduction of societal risk factors and improvement of access to care for people with depression and anxiety disorders. Sustained interventions are needed to encourage the collaboration of international and local governments as well as private organisations to decrease the stigmatisation of psychiatric conditions, to increase the number of mental-health practitioners, and to make drugs available.^{19,20} In HIV/AIDS, anti-retroviral therapy and societal-level interventions are needed in resource-poor countries.¹ Adequate resources also need to be made available to address depression and anxiety disorders in these regions.

**Dan J Stein, Oye Gureje*

Department of Psychiatry, University of Stellenbosch, Cape Town 7505, South Africa (DJS); and Department of Psychiatry, University of Ibadan, Ibadan, Nigeria (OG)
djs2@sun.ac.za

DJS is supported by the Medical Research Council of South Africa. The MRC Unit on Anxiety Disorders has received funding from drug companies in South Africa. DJS and OG have also received research grants and speaker's honoraria from several drug companies.

- 1 UNAIDS. Accelerating action against AIDS in Africa. Geneva: UNAIDS, 2003.
- 2 Patel V, Kleinman A. Poverty and common mental disorders in developing countries. *Bull WHO* 2003; **81**: 609–15.
- 3 Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA* 2004; **291**: 2581–90.
- 4 Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. *Br J Psychiatry* 2004; **184**: 386–92.
- 5 Nesse RM. Is depression an adaptation? *Arch Gen Psychiatry* 2000; **57**: 14–20.
- 6 Yehuda R, McFarlane AC. Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis. *Am J Psychiatry* 1995; **152**: 1705–13.
- 7 Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. *Am J Psychiatry* 2004; **161**: 195–216.
- 8 Patel V, Chisholm D, Rabe-Hesketh S, et al. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial. *Lancet* 2003; **361**: 33–39.
- 9 Bolton P, Bass J, Neugebauer R, et al. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. *JAMA* 2003; **289**: 3117–24.
- 10 Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. *Lancet* 2003; **361**: 995–1000.
- 11 Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. *Br J Psychiatry* 2004; **164**: 393–403.
- 12 Foucault M. The birth of the clinic: an archaeology of medical perception. New York: Random House, 1977.
- 13 Conrad P, Schneider J. Deviance and medicalization: from badness to sickness. St Louis: Mosby, 1980.
- 14 Global Forum for Health Research. The 10/90 report on health research 2003–2004. May, 2004: http://www.globalforumhealth.org/pages/index.asp?ThePage=page1_420.asp (accessed July 12, 2004).
- 15 Carey PD, Stein DJ, Zungu-Dirwayi N. Trauma and posttraumatic stress disorder in an urban Xhosa primary care population: prevalence, co-morbidity and service use patterns. *J Nerv Ment Dis* 2004; **191**: 230–36.
- 16 Zungu-Dirwayi N, Kaminer D, Mbanga I, Stein DJ. The psychiatric sequelae of human rights violations: a challenge for primary health care. *J Nerv Ment Dis* 2004; **192**: 255–59.
- 17 Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. *Acta Psychiatr Scand* 2000; **406** (suppl): 7–13.
- 18 Stein DJ, Wessels C, Zungu-Dirwayi N, Berk M, Wilson Z. Value and effectiveness of consumer advocacy groups: a survey of the anxiety disorders support group in South Africa. *Depression Anxiety* 2001; **13**: 105–07.
- 19 Resnik DB. Developing drugs for the developing world: an economic, legal, moral, and political dilemma. *Dev World Bioeth* 2001; **1**: 11–32.
- 20 Gureje O, Alem A. Mental health policy developments in Africa. *Bull World Health Organ* 2000; **78**: 475–82.

Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.